Gilead, Glaxo Wellcome Inc. deal

The companies extended for five years their 1990 collaboration to develop genetic code blocker technology, including antisense.

Under the agreement, Glaxo Wellcome will fund GILD's research in the code blocker field, and will have the primary right to develop products identified during the collaboration. GILD also will be eligible for milestones and royalties. ...